Chugai Pharmaceutical Co. Ltd (CHGCF) 35.3785 $CHGCF
Comprehensive Collaboration Agreement between Osaka University and Chugai
BusinessWire - Thu May 19, 1:30AM CDT
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519):
Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD
BusinessWire - Sat Mar 05, 11:30AM CST
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the results of global phase II study of anti-IL-31 receptor A, humanized monoclonal antibody, nemolizumab (CIM331), which is currently developed for atopic dermatitis, were released at the annual meeting of the American Academy of Dermatology currently held in Washington, D.C. The results were released at the Late-breaking Research Forums at 10:00 on Saturday, March 5 (local time).
Chugai's ALK Inhibitor "Alecensa(R)" Trial Stopped Early for Benefit
BusinessWire - Wed Feb 10, 3:49AM CST
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it received a recommendation by an independent data monitoring committee (IDMC) that the J-ALEX Study, a phase III study targeting ALK fusion gene positive non-small cell lung cancer (NSCLC) being conducted in Japan, should be stopped early as the study met its primary endpoint at a pre-planned interim analysis. The study showed that patients lived significantly longer without disease worsening (progression-free survival, PFS) when treated with Alecensa(R) compared to crizotinib.
Pruritus Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/gp95f6/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pruritus Overview - Therapeutics Development - Pipeline Products for Pruritus - Overview - Pipeline Products for Pruritus - Comparative Analysis - Pruritus - Therapeutics under Development by Companies - Pruritus - Therapeutics under Investigation by Universities/Institutes - Pruritus - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pruritus - Products under Development by Companies - Pruritus - Products under Investigation by Universities/Institutes - Pruritus - Companies Involved in Therapeutics Development - AlbireoPharma - Amorepacific Corporation - Cara Therapeutics, Inc. - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - ELORAC, Inc. - FAES Farma SA - GlaxoSmithKline Plc - Helsinn Healthcare S.A. - Hydra Biosciences, Inc. - LEO Pharma A/S - Merck & Co., Inc. - NeRRe Therapeutics Ltd - Nippon Shinyaku Co., Ltd. - Phosphagenics Limited - RDD Pharma Ltd. - Shionogi & Co., Ltd. - Tioga Pharmaceuticals, Inc. - Trevi Therapeutics, Inc. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/gp95f6/pruritus
VNDA: 10.86 (-0.07), MRK: 55.89 (-1.61), GSK: 40.33 (-0.24)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 3.22 (-0.28), GSK: 40.33 (-0.24), MEIP: 1.27 (-0.06), AAAP: 28.50 (-0.50), MACK: 6.14 (-0.19), PGNX: 4.62 (-0.12), BLCM: 12.18 (-0.56), CYCC: 5.48 (+0.15), RXDX: 5.16 (-0.27), MRK: 55.89 (-1.61), AZN: 27.58 (-0.05), JUNO: 42.40 (-0.54), CBLI: 2.51 (-0.07), NVS: 77.91 (+1.02), CELGZ: 1.47 (+0.14)
World Atopic Dermatitis Therapeutics Pipeline Report 2015
M2 - Thu Jan 14, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmkzdg/atopic_dermatitis) has announced the addition of the "Atopic Dermatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Atopic Dermatitis Overview - Therapeutics Development - Pipeline Products for Atopic Dermatitis - Overview - Pipeline Products for Atopic Dermatitis - Comparative Analysis - Atopic Dermatitis - Therapeutics under Development by Companies - Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes - Atopic Dermatitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Atopic Dermatitis - Products under Development by Companies - Atopic Dermatitis - Products under Investigation by Universities/Institutes - Atopic Dermatitis - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - Abeome Corporation - AlbireoPharma - Almirall, S.A. - Amgen Inc. - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Celgene Corporation - ChemoCentryx, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Dr. August Wolff GmbH & Co. KG Arzneimittle - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline Plc - Glenmark Pharmaceuticals Ltd. - Grupo Ferrer Internacional, S.A. - Han Wha Pharma Co., Ltd. - HanAll Biopharma Co., Ltd. - Herantis Pharma Plc - iCo Therapeutics Inc. - IMMD Inc. - Immune Pharmaceuticals Inc. - Inflamalps SA For more information visit http://www.researchandmarkets.com/research/zm...dermatitis
AQXP: 6.49 (-0.45), FOMX: 5.97 (-0.04), AMGN: 149.62 (-2.68), IMNP: 0.41 (-0.05), GSK: 40.33 (-0.24), DERM: 28.90 (-0.87), CCXI: 4.75 (-0.05), ANAC: 99.17 (-0.07), CELGZ: 1.47 (+0.14)
Chugai's ALK Inhibitor "Alecensa(R)" Accelerated Approval in Three Months after Priority Review Designation in the US
BusinessWire - Mon Dec 14, 12:34AM CST
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Genentech Inc., a member of the Roche Group, obtained approval from the U.S. Food and Drug Administration (FDA), for the anti-cancer agent, alectinib hydrochloride (brand name: Alecensa(R)) for the indication of "anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or those intolerant to crizotinib."
Chugai Pharmaceutical Opens a North American Hub in New Jersey
PR Newswire - Fri Nov 20, 9:00AM CST
Today, Chugai Pharma USA Inc. (CPUSA), a wholly-owned subsidiary of Chugai Pharmaceutical Co, Ltd. (Chugai), announced the official opening of its new office, dedicated to translational clinical research, located in Berkeley Heights, N.J. The facility serves as the hub for Chugai, the research-based pharmaceutical company headquartered in Tokyo. Chugai initiated activities in the U.S. in 1982; in response to increasing industry competition, CPUSA is now focused on Early Development and, in spring of this year established Chugai's Translational Clinical Research Division (TCRD).
Athersys Updates on Development Strategy in Japan
GlobeNewswire - Wed Oct 21, 5:30AM CDT
Athersys, Inc. ("Athersys"
(NASDAQ:ATHX) announced today that Athersys and Chugai Pharmaceutical Co., Ltd. ("Chugai" have ended the license agreement between them for the exclusive development and commercialization of MultiStem cell therapy for ischemic stroke in Japan. The parties were unable to reach an agreement on the modification of the financial terms of the agreement and on development strategy in Japan, in light of the results from the Phase 2 clinical study. All rights will revert to Athersys, and Athersys will retain the $10 million license fee paid by Chugai.
ATHX: 2.16 (-0.03)
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 3.64 (-0.04), ADXS: 8.03 (-0.35), BMRN: 83.86 (+3.06), CERU: 2.10 (unch), AMBX: (), CLDX: 4.27 (-0.14), AMGN: 149.62 (-2.68), BMY: 70.67 (-1.06), AZN: 27.58 (-0.05), AVEO: 1.02 (+0.08), ABBV: 60.01 (-0.89), CELGZ: 1.47 (+0.14)
Company Profile for Chugai Pharmaceutical Co., Ltd.
BusinessWire - Thu Oct 01, 7:10PM CDT
Chugai Pharmaceutical (TOKYO:4519) is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai's proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo(R)) in the UK by Chugai Pharma UK Ltd.
BusinessWire - Thu Sep 10, 1:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and a wholly owned subsidiary of Chugai, Chugai Pharma Marketing Ltd. [Head Office: London, the UK; Managing Director: John Halls] (CPM) and Helsinn Group [Head Office: Lugano, Switzerland; CEO: Riccardo Braglia], the Swiss Group focused on building quality cancer care, today announced that Akynzeo(R), an oral fixed-dose combination of netupitant (highly-selective NK1 receptor antagonist) and palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), has been launched by a wholly owned subsidiary of CPM, Chugai Pharma UK Ltd. [Head Office: London, the UK; Managing Director: Ruth Currie] (CPU), in the UK as from September 1, 2015. CPM has been granted the exclusive right of Akynzeo for sales and marketing from Helsinn Healthcare S.A.
Chugai's ALK Inhibitor "Alectinib," New Drug Application Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer in the United States
BusinessWire - Wed Sep 09, 12:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] (Roche) announced today that Genentech, Inc. [Head Office: California, U.S., CEO: Ian T. Clark], a member of the Roche Group, has filed a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) and the FDA has accepted the NDA, for ALK (Anaplastic Lymphoma Kinase) inhibitor "alectinib hydrochloride" (alectinib) for the treatment of patient with ALK positive advanced non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib in September.
Chugai's Bispecific Antibody "ACE910" for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA
BusinessWire - Fri Sep 04, 12:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] (hereafter, "Chugai" announced today that the US Food and Drug Administration (FDA) has granted the Breakthrough Therapy Designation to "ACE910," for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors.
Neuroblastoma Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Neuroblastoma
M2 - Mon Aug 17, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9kbwkd/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2015" report to their offering. Summary This, Neuroblastoma - Pipeline Review, H1 2015', provides an overview of the Neuroblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Aeterna Zentaris Inc. - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - Aptose Biosciences Inc. - AstraZeneca Plc - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - Gamida Cell Ltd. - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Netris Pharma S.A.S. - Novartis AG - Novogen Limited - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/9k...roblastoma
AMPE: 3.22 (-0.28), AAAP: 28.50 (-0.50), MACK: 6.14 (-0.19), PGNX: 4.62 (-0.12), APTO: 2.70 (-0.10), BLCM: 12.18 (-0.56), RXDX: 5.16 (-0.27), AZN: 27.58 (-0.05), MRK: 55.89 (-1.61), JUNO: 42.40 (-0.54), CBLI: 2.51 (-0.07), NVS: 77.91 (+1.02), CELGZ: 1.47 (+0.14)
Neuromyelitis Optica (Devic's Syndrome) Pipeline Report 2015 - 9 Companies & 10 Drug Profiles
M2 - Thu May 21, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34rhhd/neuromyelitis) has announced the addition of the "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Alexion Pharmaceuticals, Inc. - Chugai Pharmaceutical Co., Ltd. - HanAll Biopharma Co., Ltd. - MedImmune, LLC - Opexa Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Takeda Pharmaceutical Company Limited Drug Profiles - C1 esterase inhibitor (human) - dalfampridine ER - Dendritic Cell Therapy for Central Nervous System Disorders - eculizumab - HL-161 - immune globulin (human) - MEDI-551 - NU-21101 NU-21502 - OPX-212 - SA-237 For more information visit http://www.researchandmarkets.com/research/34...romyelitis
OPXA: 3.43 (+0.12), SHPG: 168.82 (-2.29), ALXN: 125.20 (-2.29), ACOR: 25.75 (-0.02)
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 13.97 (+0.38), ARWR: 5.74 (-0.19), ACHN: 8.52 (-0.58), CNAT: 1.92 (-0.01), ANAC: 99.17 (-0.07), ABBV: 60.01 (-0.89), BMY: 70.67 (-1.06), CELGZ: 1.47 (+0.14)
Global Gastric Cancer Pipeline Report 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/527p3s/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastric Cancer Overview - Therapeutics Development - Gastric Cancer - Therapeutics under Development by Companies - Gastric Cancer - Therapeutics under Investigation by Universities/Institutes - Gastric Cancer - Pipeline Products Glance - Gastric Cancer - Products under Development by Companies - Gastric Cancer - Products under Investigation by Universities/Institutes - Gastric Cancer - Companies Involved in Therapeutics Development - Gastric Cancer - Therapeutics Assessment - Drug Profiles - Gastric Cancer - Recent Pipeline Updates - Gastric Cancer - Dormant Projects - Gastric Cancer - Discontinued Products - Gastric Cancer - Product Development Milestones - Appendix Companies Mentioned: Partial List - AB Science - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Covagen AG - DAE HWA Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Galena Biopharma, Inc. - Genentech, Inc. - GlaxoSmithKline plc - GlycoNex Inc. - Glycotope GmbH - ISU ABXIS Co.,Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Kadmon Corporation, LLC - Millennium Pharmaceuticals, Inc. - Molecular Targeting Technologies, Inc. - MSM Protein Technologies, Inc. - NanoCarrier Co., Ltd. - NeoPharm Co., Ltd. - Novartis AG - Regulon Inc. - Rexahn Pharmaceuticals, Inc. - Richter Gedeon Nyrt. - Sanofi - Sareum Holdings plc - SentoClone International AB - Sequella, Inc. - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/52...ric_cancer
RNN: 0.25 (-0.01), GALE: 2.22 (+0.07), GSK: 40.33 (-0.24), NVS: 77.91 (+1.02)
Selection of Board Member Candidates
M2 - Thu Apr 30, 5:27AM CDT
The candidates for election to the position of Member of the Board are as follows.Kazuo Hirai Representative Corporate Executive Officer, President and CEO Kenichiro Yoshida Representative Corporate Executive Officer, Executive Deputy President and CFO Kanemitsu Anraku(*) Director, Mizuho Financial Group, Inc. Osamu Nagayama(*) Representative Director, Chairman and Chief Executive Officer, Chugai Pharmaceutical Co., Ltd. Takaaki Nimura(*) Certified Public Accountant Eikoh Harada(*) Representative Director, Chairman and CEO, Benesse Holdings, Inc.
MFG: 2.98 (+0.03)
Comprehensive Collaboration Agreement between Osaka University and Chugai
BusinessWire - Thu May 19, 1:30AM CDT
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519):
Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD
BusinessWire - Sat Mar 05, 11:30AM CST
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the results of global phase II study of anti-IL-31 receptor A, humanized monoclonal antibody, nemolizumab (CIM331), which is currently developed for atopic dermatitis, were released at the annual meeting of the American Academy of Dermatology currently held in Washington, D.C. The results were released at the Late-breaking Research Forums at 10:00 on Saturday, March 5 (local time).
Chugai's ALK Inhibitor "Alecensa(R)" Trial Stopped Early for Benefit
BusinessWire - Wed Feb 10, 3:49AM CST
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it received a recommendation by an independent data monitoring committee (IDMC) that the J-ALEX Study, a phase III study targeting ALK fusion gene positive non-small cell lung cancer (NSCLC) being conducted in Japan, should be stopped early as the study met its primary endpoint at a pre-planned interim analysis. The study showed that patients lived significantly longer without disease worsening (progression-free survival, PFS) when treated with Alecensa(R) compared to crizotinib.
Pruritus Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/gp95f6/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pruritus Overview - Therapeutics Development - Pipeline Products for Pruritus - Overview - Pipeline Products for Pruritus - Comparative Analysis - Pruritus - Therapeutics under Development by Companies - Pruritus - Therapeutics under Investigation by Universities/Institutes - Pruritus - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pruritus - Products under Development by Companies - Pruritus - Products under Investigation by Universities/Institutes - Pruritus - Companies Involved in Therapeutics Development - AlbireoPharma - Amorepacific Corporation - Cara Therapeutics, Inc. - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - ELORAC, Inc. - FAES Farma SA - GlaxoSmithKline Plc - Helsinn Healthcare S.A. - Hydra Biosciences, Inc. - LEO Pharma A/S - Merck & Co., Inc. - NeRRe Therapeutics Ltd - Nippon Shinyaku Co., Ltd. - Phosphagenics Limited - RDD Pharma Ltd. - Shionogi & Co., Ltd. - Tioga Pharmaceuticals, Inc. - Trevi Therapeutics, Inc. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/gp95f6/pruritus
VNDA: 10.86 (-0.07), MRK: 55.89 (-1.61), GSK: 40.33 (-0.24)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 3.22 (-0.28), GSK: 40.33 (-0.24), MEIP: 1.27 (-0.06), AAAP: 28.50 (-0.50), MACK: 6.14 (-0.19), PGNX: 4.62 (-0.12), BLCM: 12.18 (-0.56), CYCC: 5.48 (+0.15), RXDX: 5.16 (-0.27), MRK: 55.89 (-1.61), AZN: 27.58 (-0.05), JUNO: 42.40 (-0.54), CBLI: 2.51 (-0.07), NVS: 77.91 (+1.02), CELGZ: 1.47 (+0.14)
World Atopic Dermatitis Therapeutics Pipeline Report 2015
M2 - Thu Jan 14, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmkzdg/atopic_dermatitis) has announced the addition of the "Atopic Dermatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Atopic Dermatitis Overview - Therapeutics Development - Pipeline Products for Atopic Dermatitis - Overview - Pipeline Products for Atopic Dermatitis - Comparative Analysis - Atopic Dermatitis - Therapeutics under Development by Companies - Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes - Atopic Dermatitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Atopic Dermatitis - Products under Development by Companies - Atopic Dermatitis - Products under Investigation by Universities/Institutes - Atopic Dermatitis - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - Abeome Corporation - AlbireoPharma - Almirall, S.A. - Amgen Inc. - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Celgene Corporation - ChemoCentryx, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Dr. August Wolff GmbH & Co. KG Arzneimittle - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline Plc - Glenmark Pharmaceuticals Ltd. - Grupo Ferrer Internacional, S.A. - Han Wha Pharma Co., Ltd. - HanAll Biopharma Co., Ltd. - Herantis Pharma Plc - iCo Therapeutics Inc. - IMMD Inc. - Immune Pharmaceuticals Inc. - Inflamalps SA For more information visit http://www.researchandmarkets.com/research/zm...dermatitis
AQXP: 6.49 (-0.45), FOMX: 5.97 (-0.04), AMGN: 149.62 (-2.68), IMNP: 0.41 (-0.05), GSK: 40.33 (-0.24), DERM: 28.90 (-0.87), CCXI: 4.75 (-0.05), ANAC: 99.17 (-0.07), CELGZ: 1.47 (+0.14)
Chugai's ALK Inhibitor "Alecensa(R)" Accelerated Approval in Three Months after Priority Review Designation in the US
BusinessWire - Mon Dec 14, 12:34AM CST
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Genentech Inc., a member of the Roche Group, obtained approval from the U.S. Food and Drug Administration (FDA), for the anti-cancer agent, alectinib hydrochloride (brand name: Alecensa(R)) for the indication of "anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or those intolerant to crizotinib."
Chugai Pharmaceutical Opens a North American Hub in New Jersey
PR Newswire - Fri Nov 20, 9:00AM CST
Today, Chugai Pharma USA Inc. (CPUSA), a wholly-owned subsidiary of Chugai Pharmaceutical Co, Ltd. (Chugai), announced the official opening of its new office, dedicated to translational clinical research, located in Berkeley Heights, N.J. The facility serves as the hub for Chugai, the research-based pharmaceutical company headquartered in Tokyo. Chugai initiated activities in the U.S. in 1982; in response to increasing industry competition, CPUSA is now focused on Early Development and, in spring of this year established Chugai's Translational Clinical Research Division (TCRD).
Athersys Updates on Development Strategy in Japan
GlobeNewswire - Wed Oct 21, 5:30AM CDT
Athersys, Inc. ("Athersys"
(NASDAQ:ATHX) announced today that Athersys and Chugai Pharmaceutical Co., Ltd. ("Chugai" have ended the license agreement between them for the exclusive development and commercialization of MultiStem cell therapy for ischemic stroke in Japan. The parties were unable to reach an agreement on the modification of the financial terms of the agreement and on development strategy in Japan, in light of the results from the Phase 2 clinical study. All rights will revert to Athersys, and Athersys will retain the $10 million license fee paid by Chugai. ATHX: 2.16 (-0.03)
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 3.64 (-0.04), ADXS: 8.03 (-0.35), BMRN: 83.86 (+3.06), CERU: 2.10 (unch), AMBX: (), CLDX: 4.27 (-0.14), AMGN: 149.62 (-2.68), BMY: 70.67 (-1.06), AZN: 27.58 (-0.05), AVEO: 1.02 (+0.08), ABBV: 60.01 (-0.89), CELGZ: 1.47 (+0.14)
Company Profile for Chugai Pharmaceutical Co., Ltd.
BusinessWire - Thu Oct 01, 7:10PM CDT
Chugai Pharmaceutical (TOKYO:4519) is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai's proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo(R)) in the UK by Chugai Pharma UK Ltd.
BusinessWire - Thu Sep 10, 1:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and a wholly owned subsidiary of Chugai, Chugai Pharma Marketing Ltd. [Head Office: London, the UK; Managing Director: John Halls] (CPM) and Helsinn Group [Head Office: Lugano, Switzerland; CEO: Riccardo Braglia], the Swiss Group focused on building quality cancer care, today announced that Akynzeo(R), an oral fixed-dose combination of netupitant (highly-selective NK1 receptor antagonist) and palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), has been launched by a wholly owned subsidiary of CPM, Chugai Pharma UK Ltd. [Head Office: London, the UK; Managing Director: Ruth Currie] (CPU), in the UK as from September 1, 2015. CPM has been granted the exclusive right of Akynzeo for sales and marketing from Helsinn Healthcare S.A.
Chugai's ALK Inhibitor "Alectinib," New Drug Application Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer in the United States
BusinessWire - Wed Sep 09, 12:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] (Roche) announced today that Genentech, Inc. [Head Office: California, U.S., CEO: Ian T. Clark], a member of the Roche Group, has filed a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) and the FDA has accepted the NDA, for ALK (Anaplastic Lymphoma Kinase) inhibitor "alectinib hydrochloride" (alectinib) for the treatment of patient with ALK positive advanced non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib in September.
Chugai's Bispecific Antibody "ACE910" for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA
BusinessWire - Fri Sep 04, 12:00AM CDT
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] (hereafter, "Chugai"
announced today that the US Food and Drug Administration (FDA) has granted the Breakthrough Therapy Designation to "ACE910," for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors. Neuroblastoma Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Neuroblastoma
M2 - Mon Aug 17, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9kbwkd/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2015" report to their offering. Summary This, Neuroblastoma - Pipeline Review, H1 2015', provides an overview of the Neuroblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Aeterna Zentaris Inc. - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - Aptose Biosciences Inc. - AstraZeneca Plc - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - Gamida Cell Ltd. - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Netris Pharma S.A.S. - Novartis AG - Novogen Limited - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/9k...roblastoma
AMPE: 3.22 (-0.28), AAAP: 28.50 (-0.50), MACK: 6.14 (-0.19), PGNX: 4.62 (-0.12), APTO: 2.70 (-0.10), BLCM: 12.18 (-0.56), RXDX: 5.16 (-0.27), AZN: 27.58 (-0.05), MRK: 55.89 (-1.61), JUNO: 42.40 (-0.54), CBLI: 2.51 (-0.07), NVS: 77.91 (+1.02), CELGZ: 1.47 (+0.14)
Neuromyelitis Optica (Devic's Syndrome) Pipeline Report 2015 - 9 Companies & 10 Drug Profiles
M2 - Thu May 21, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34rhhd/neuromyelitis) has announced the addition of the "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Alexion Pharmaceuticals, Inc. - Chugai Pharmaceutical Co., Ltd. - HanAll Biopharma Co., Ltd. - MedImmune, LLC - Opexa Therapeutics, Inc. - Shenzhen Beike Biotechnology Co., Ltd. - Shire Plc - Takeda Pharmaceutical Company Limited Drug Profiles - C1 esterase inhibitor (human) - dalfampridine ER - Dendritic Cell Therapy for Central Nervous System Disorders - eculizumab - HL-161 - immune globulin (human) - MEDI-551 - NU-21101 NU-21502 - OPX-212 - SA-237 For more information visit http://www.researchandmarkets.com/research/34...romyelitis
OPXA: 3.43 (+0.12), SHPG: 168.82 (-2.29), ALXN: 125.20 (-2.29), ACOR: 25.75 (-0.02)
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 13.97 (+0.38), ARWR: 5.74 (-0.19), ACHN: 8.52 (-0.58), CNAT: 1.92 (-0.01), ANAC: 99.17 (-0.07), ABBV: 60.01 (-0.89), BMY: 70.67 (-1.06), CELGZ: 1.47 (+0.14)
Global Gastric Cancer Pipeline Report 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/527p3s/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Gastric Cancer Overview - Therapeutics Development - Gastric Cancer - Therapeutics under Development by Companies - Gastric Cancer - Therapeutics under Investigation by Universities/Institutes - Gastric Cancer - Pipeline Products Glance - Gastric Cancer - Products under Development by Companies - Gastric Cancer - Products under Investigation by Universities/Institutes - Gastric Cancer - Companies Involved in Therapeutics Development - Gastric Cancer - Therapeutics Assessment - Drug Profiles - Gastric Cancer - Recent Pipeline Updates - Gastric Cancer - Dormant Projects - Gastric Cancer - Discontinued Products - Gastric Cancer - Product Development Milestones - Appendix Companies Mentioned: Partial List - AB Science - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Covagen AG - DAE HWA Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Galena Biopharma, Inc. - Genentech, Inc. - GlaxoSmithKline plc - GlycoNex Inc. - Glycotope GmbH - ISU ABXIS Co.,Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Kadmon Corporation, LLC - Millennium Pharmaceuticals, Inc. - Molecular Targeting Technologies, Inc. - MSM Protein Technologies, Inc. - NanoCarrier Co., Ltd. - NeoPharm Co., Ltd. - Novartis AG - Regulon Inc. - Rexahn Pharmaceuticals, Inc. - Richter Gedeon Nyrt. - Sanofi - Sareum Holdings plc - SentoClone International AB - Sequella, Inc. - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/52...ric_cancer
RNN: 0.25 (-0.01), GALE: 2.22 (+0.07), GSK: 40.33 (-0.24), NVS: 77.91 (+1.02)
Selection of Board Member Candidates
M2 - Thu Apr 30, 5:27AM CDT
The candidates for election to the position of Member of the Board are as follows.Kazuo Hirai Representative Corporate Executive Officer, President and CEO Kenichiro Yoshida Representative Corporate Executive Officer, Executive Deputy President and CFO Kanemitsu Anraku(*) Director, Mizuho Financial Group, Inc. Osamu Nagayama(*) Representative Director, Chairman and Chief Executive Officer, Chugai Pharmaceutical Co., Ltd. Takaaki Nimura(*) Certified Public Accountant Eikoh Harada(*) Representative Director, Chairman and CEO, Benesse Holdings, Inc.
MFG: 2.98 (+0.03)
